US Pharma MarketingQ&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research
Seaport Therapeutics began trading as a public company on Friday, after executives rang the Nasdaq’s opening bell. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug…
Seaport Therapeutics began trading as a public company on Friday after executives rang the Nasdaq’s opening bell. Shares rose {$SPTX} more than 20%.
With a team largely made up of Karuna Therapeutics veterans, Seaport is ...
Source: Endpoints News